Elsevier

Tubercle

Volume 72, Issue 1, March 1991, Pages 13-20

Review paper
Cytokines and the Koch phenomenon

https://doi.org/10.1016/0041-3879(91)90019-OGet rights and content

Abstract

We outline the mechanisms contributing to the human form of the Koch phenomenon, which we define as necrosis occurring within 24–48 h of injection of mycobacterial antigen into the skin of past or present tuberculosis patients. It is probable that tissue damage mediated in the same way occurs in the lesions themselves. We suggest that the necrosis is mediated in part by cytokines, particularly Tumour Necrosis Factor (TNF), and that this occurs for three reasons. First, Mycobacterium tuberculosis evokes an immunoregulatory abnormality characterised by raised agalactosyl IgG. This abnormality, also found in rheumatoid arthritis, Crohn's disease, and Erythema Nodosum Leprosum, seems to be associated with dysregulation of cytokine release. Secondly, M. tuberculosis itself triggers further cytokine release. Thirdly, the normally protective role of TNF is distorted by several interacting properties of components of M. tuberculosis, which render the cytokine toxic to the host tissues.

The immunoregulatory abnormality may be susceptible to correction by immunotherapy.

References (50)

  • G.A.W. Rook et al.

    Vitamin D3, gamma interferon, and control of proliferation ofMycobacterium tuberculosis by human monocytes

    Immunology

    (1986)
  • A.E. Brown et al.

    Capacity of human neutrophils to kill Mycobacterium tuberculosis

    J Infect Dis

    (1987)
  • S.H.E. Kaufmann et al.

    Effector T cells in bacterial infections in

  • G.A.W. Rook

    The role of vitamin D in tuberculosis

    Amer Rev Resp Dis

    (1988)
  • A.J. Crowle et al.

    Inhibition by 1,25(OH)2vitamin D3 of the multiplication of virulent tubercle bacilli in cultured human macrophages

    Infect Immun

    (1987)
  • G.A.W. Rook et al.

    The role of gamma interferon, vitamin D metabolites and tumour necrosis factor in the pathogenesis of tuberculosis

    Immunology

    (1987)
  • D.E. Macrae

    Calciferol treatment of lupus vulgaris

    Brit J Dermatol

    (1947)
  • J. Brincourt

    Le calcifrol a-t-il une action liqufiante sur la casum?

    Poumon Coeur

    (1967)
  • G.A.W. Rook et al.

    What mediates the immunological component of the immune response to Mycobacterium tuberculosis? Can it be switched off?

    Bull IUATLD

    (1990)
  • C. Moreno et al.

    Lipoarabinomannan from Mycobacterium tuberculosis induces the production of tumour necrosis factor from human and murine macrophages

    Clin Exp Immunol

    (1989)
  • C.L. Silva et al.

    Mouse cachexia induced by trehalose dimycolate from Nocardiaasteroides

    J Gen Microbiol

    (1988)
  • N. Foley et al.

    An inhibitor of the toxicity of tumour necrosis factor in the serum of patients with sarcoidosis, tuberculosis and Crohn's disease

    Clin Exp Immunol

    (1990)
  • B. Beutler et al.

    Cachectin and tumour necrosis factor as two sides of the same biological coin

    Nature

    (1986)
  • K.J. Tracey et al.

    Anti-cachectin/TNF monoclonal antibodies prevent septic shock during lethal bacteraemia

    Nature

    (1987)
  • A.S. Cross et al.

    Pretreatment with recombinant murine tumour necrosis factor/cachectin and marine interleukin 1 protects mice from lethal bacterial infection

    J Exp Med

    (1989)
  • Cited by (76)

    • Preferred product characteristics for therapeutic vaccines to improve tuberculosis treatment outcomes: Key considerations from World Health Organization consultations

      2020, Vaccine
      Citation Excerpt :

      For initial proof-of-concept generation, the administration of vaccines at the end of treatment in individuals enrolled only after end of treatment delivered in a routine setting, may be an appropriate way of mitigating the generalizability question. The potential for the injection of antigenic components of Mtb precipitating a delayed-type (Type IV) hypersensitivity reaction, resulting in necrosis at the site of injection, in persons with Mtb infection or active TB [37] represents a possibility that must be considered when testing therapeutic TB vaccines on persons with active TB disease. The possibility of pulmonary and systemic inflammatory reactions [38] , and the breakdown of granuloma structure potentially resulting in Mtb dissemination should be considered and monitored.

    • Safety and immunogenicity of the M72/AS01<inf>E</inf> candidate tuberculosis vaccine in adults with tuberculosis: A phase II randomised study

      2016, Tuberculosis
      Citation Excerpt :

      The increased reactogenicity could also be caused by an extreme form of delayed hypersensitivity, similar to previously reported exaggerated reactions to the Mantoux test [36,37]. In contrast, the increased reactogenicity was unlikely to be due to Koch reactions, which correspond to disease exacerbations in M. tuberculosis-infected individuals upon newly exposure to mycobacterial compounds [33,38]. Although the immunological mechanism behind the Koch phenomenon is not known, the absence of AEs suggestive of pulmonary pathology indicated that the vaccine did not induce lung inflammation and that Koch reactions did not lie behind the large, self-resolving (without sequel) skin reactions in TB-infected patients [39].

    • Mycobacterium tuberculosis PE25/PPE41 protein complex induces necrosis in macrophages: Role in virulence and disease reactivation?

      2014, FEBS Open Bio
      Citation Excerpt :

      M. tuberculosis induces apoptosis in APCs through TNF-α, toll like receptors (TLRs), Fas or by altering the expression of Bax/Bcl-xL via an oxygen dependent pathway [1–4]. Virulent strains of M. tuberculosis have been known to develop mechanisms that resist host apoptotic cell death [5–8], however they are capable of inducing necrotic cell death, which helps in bacterial multiplication and dissemination [9–12]. On the other hand non-virulent strains like Mycobacterium bovis BCG and Mycobacterium smegmatis fail to induce necrosis of the host cells [10,11], suggesting that the factors released by the virulent strains interfere with the host cell death machinery for their release and subsequent infection of the neighboring (fresh) cells [8].

    • Nonlytic Fc-fused IL-7 synergizes with Mtb32 DNA vaccine to enhance antigen-specific T cell responses in a therapeutic model of tuberculosis

      2013, Vaccine
      Citation Excerpt :

      The discrepancy may reflect differences in pathogen (LCMV vs. MTB), concentration of IL-7 (5 μg of protein which daily injected for 25 days vs. 50 μg of DNA plasmid five times with two week intervals), and timing of treatment (contraction phase vs. under chemotherapy) [18,30–32]. Safety issues of TB therapeutic vaccines were raised after a subcutaneous injection of culture filtrate into tuberculosis patients evoked necrosis in established tuberculosis lesions at distant sites, which is now known as the “Koch reaction” and implicates the development of immunopathology due to severe inflammation reaction caused by exaggerated immune response to MTB [33]. It is therefore noteworthy to mention a recent study that evaluated the effects of recombinant human IL-7 (rhIL-7) in a sepsis model showed improved survival, indicating that diminished exacerbation was the result of highly activated immune cells [16].

    • N-3 Fatty acids uniquely affect anti-microbial resistance and immune cell plasma membrane organization

      2011, Chemistry and Physics of Lipids
      Citation Excerpt :

      For example, IL-12 is critical for activation and migration of murine dendritic cells (Cooper et al., 1995) and TNFα is required for granuloma formation in mice (Flynn et al., 1995). On the other hand, TNFα is also associated with the histopathological damage during TB, mediating necrosis and tissue dysfunction (Rook and al Attiyah, 1991). Lipids serve as structural membrane components, a source of energy and regulators of the host immune response.

    View all citing articles on Scopus
    View full text